Scarica l'app Stockscreener
55.97
1.80%
0.99
Dopo l'orario di chiusura:
55.40
-0.57
-1.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna (MRNA) and BioNTech (BNTX) Shares Rise on Advisory Rever - GuruFocus
Moderna Settles Patent Litigation with Arbutus et al. - JD Supra
Is It Too Early To Reassess Moderna (MRNA) After Its Strong 2024 Share Price Rally? - simplywall.st
Jefferies Financial Group Reduces Moderna Stake - National Today
Jefferies Financial Group Inc. Sells 32,310 Shares of Moderna, Inc. $MRNA - MarketBeat
US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports - Reuters
Moderna: Pipeline Hope Won't Pay The Bills (NASDAQ:MRNA) - Seeking Alpha
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges - GuruFocus
Moderna Stock Hits Day High with 6.13% Surge, Outperforming S&P 500 - Markets Mojo
BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture - Benzinga
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Lyme Disease Vaccine Market Is Booming So Rapidly | Valneva SE • Pfizer Inc. • Moderna Inc - openPR.com
Quantbot Technologies LP Sells 34,481 Shares of Moderna, Inc. $MRNA - MarketBeat
MRNA Stock Quote Price and Forecast - CNN
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Moderna surges after hours on patent settlement with Arbutus and Genevant - MSN
Is Moderna (MRNA) Pricing Too High After Its Recent 70% Year To Date Rally - Yahoo Finance
Moderna Settlement And EMA Opinion Reframe mRNA Platform Outlook - Yahoo Finance
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - Lubbock Avalanche-Journal
Is Moderna Inc. stock attractive after correction2026 Major Catalysts & Long-Term Growth Stock Strategies - Naître et grandir
Aug Highlights: Why Moderna Inc. stock appeals to analystsTrade Entry Report & Weekly Stock Performance Updates - Naître et grandir
Moderna Stock (MRNA) Opinions on FDA Vaccines Chief Departure | MRNA Stock News - Quiver Quantitative
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Market Watch Rx: IQVIA Joins Top Gainers - Pharmaceutical Executive
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 7.6%Here's What Happened - MarketBeat
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug - RTTNews
These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next - 24/7 Wall St.
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
Best Biotech Stocks To Add to Your WatchlistMarch 5th - MarketBeat
Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit - Pharmaceutical Technology
Moderna reaches agreement in COVID-19 intellectural property dispute - Delaware Business Now
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement - FinancialContent
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - Stock Traders Daily
Moderna Resolves $950M Patent Battle Over COVID-19 Vaccine Tech—Find Out How It Impacts the Industry - Investing News Network
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era - FinancialContent
Moderna Stock Surges 16% Following Global Patent Litigation Settlement - TIKR.com
Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn - 24/7 Wall St.
Moderna, Inc. Opens with 7.53% Gain, Outperforming S&P 500's Decline - Markets Mojo
Moderna (MRNA) Reaches Settlement Agreement with Arbutus Biophar - GuruFocus
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com Nigeria
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating - marketscreener.com
Moderna Reaches Major Patent Settlement on mRNA Vaccines - TipRanks
Biotechnology giant Moderna, Inc. announced that it has committed to pay its partner Arbutus Biopharma and its subsidiary Genevant Sciences an unconditional one-time payment of up to 950 millions USD on or before July 8, 2026. - Bitget
Moderna to Pay Up to $2.25B to Settle COVID-19 Vaccine Patent Lawsuit - Lawyer Monthly
Moderna Vaccine Patent Deal Sets Up High-Stakes Immunity Appeal - Bloomberg Law News
Moderna Notches Much-Needed Win in COVID-19 Patent Spat With Roivant - BioSpace
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Claims Journal
Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears - Finviz
Moderna Settles with Genevant and Arbutus, Ending LNP Patent Dispute - IPWatchdog.com
Does $2.25 Billion LNP Settlement And Global License Reshape The Bull Case For Moderna (MRNA)? - Yahoo Finance
Moderna Settles Lipid Nanoparticle Patent-Infringement Case With Genevant/Arbutus - Citeline News & Insights
EMA Approves Moderna’s Revolutionary mCOMBRIAX Vaccine, Shares Soar - timothysykes.com
Why Moderna (MRNA) Stock Is Trading Up Today - Finviz
These Stocks Are Today’s Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More - Barron's
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology - MedCity News
U.S. Indexes Rose Wednesday; Moderna Topped Leaders - Barron's
Moderna to Pay Up to $2.25B to Settle COVID Vaccine Patent Dispute - National Today
The Sun Will Shine On Moderna AgainInitiating With A Buy (NASDAQ:MRNA) - Seeking Alpha
Moderna shares rise on $2.25-billion settlement over COVID-19 vaccine technology - The Globe and Mail
Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. - Barron's
Moderna reaches vaccine settlement, GitLab's guidance disappoints - Yahoo Finance
8.28%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):